 |
BioWorld-International-2009-12-02
Bavarian Nordic Stock Falls on Plans to Raise $50M for Vaccine
Bavarian Nordic Stock Falls on Plans to Raise $50M for Vaccine
Shares in Bavarian Nordic A/S dropped more than 3 percent Tuesday on news that the company is planning to raise DKK250 million (US$50.6 million) to DKK300 million early in the new year. (BioWorld International)
Wilex Delays Raising €14M After Good Data on Antibody
No Abstract
BioWorld International Correspondent
Wilex AG delayed completion of a capital increase because of the early arrival of positive preliminary data from a Phase III trial of its diagnostic antibody Redectane, which is in development for presurgical detection of clear cell renal cell carcinoma, the most common form of kidney cancer.